Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Human Factors

Date Submitted: Jun 25, 2024
Date Accepted: Dec 22, 2024

The final, peer-reviewed published version of this preprint can be found here:

Satisfaction and Usability of a Commercially Available Medication Adherence App (Medisafe) Among Medically Underserved Patients With Chronic Illnesses: Survey Study

Hartch C, Dietrich MS, Lancaster BJ, Mulvaney SA, Stolldorf DP

Satisfaction and Usability of a Commercially Available Medication Adherence App (Medisafe) Among Medically Underserved Patients With Chronic Illnesses: Survey Study

JMIR Hum Factors 2025;12:e63653

DOI: 10.2196/63653

PMID: 39773694

PMCID: 11751649

The Satisfaction and Usability of a Commercially Available Medication Adherence App Among Medically Underserved Patients with Chronic Illness

  • Christa Hartch; 
  • Mary S. Dietrich; 
  • B. Jeanette Lancaster; 
  • Shelagh A. Mulvaney; 
  • Deonni P. Stolldorf

ABSTRACT

Background:

Research supports the use of mobile phone apps to promote medication adherence, but there are few studies conducted with medically underserved patients with chronic illness.

Objective:

This is a study of the overall use and satisfaction with a medication adherence app that was tested within a randomized controlled efficacy trial.

Methods:

Medically underserved adults who received care for one or more chronic illnesses at a Federally Qualified Health Center (FQHC) were randomized to a group who used the app for one month (n = 30) or a control group (n = 31). Self-reported and objective use and satisfaction information in the app study group was gathered via a follow-up questionnaire and data supplied by the app company.

Results:

The participants were very satisfied with the app with all (n = 30, 100%) somewhat or strongly agreeing they would recommend the app to family and friends. Intervention group participants strongly agreed (n=28, 93.3%) that the reminders helped them remember to take their medications at the correct time each day. Participants found it easy to use (n=28, 93.3%). Additional features accessed by some included educational features and the adherence report. Participants noted the helpfulness of having a medication list on their phone and some used it during medication reconciliation at doctor visits. Use of the Medfriend feature, which alerts a social support person if the participant missed a medication, was low (n = 2), but those who used it were very positive about the feature.

Conclusions:

This study demonstrated that a commercially available medication adherence app was found useful by participants, and they were satisfied with the app and the additional features they used. The use of medication adherence mobile phone apps has the potential to positively impact chronic disease management in a medically underserved population on a larger scale. Clinical Trial: The RCT is registered at clinicaltrials.gov registry number NCT05098743


 Citation

Please cite as:

Hartch C, Dietrich MS, Lancaster BJ, Mulvaney SA, Stolldorf DP

Satisfaction and Usability of a Commercially Available Medication Adherence App (Medisafe) Among Medically Underserved Patients With Chronic Illnesses: Survey Study

JMIR Hum Factors 2025;12:e63653

DOI: 10.2196/63653

PMID: 39773694

PMCID: 11751649

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.